Approach to the diagnosis and management of common bleeding disorders

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 7, 2012, Pages 711-719

  Rydz, Natalia ^a   James, Paulad ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

bleeding scores; bruising; epistaxis; hemophilia; menorrhagia; mucocutaneous bleeding; platelet function disorder; von Willebrand disease

Indexed keywords

DESMOPRESSIN; FIBRINOGEN; ORAL CONTRACEPTIVE AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ARTICLE; BLEEDING DISORDER; BLOOD CELL COUNT; BLOOD CLOTTING DISORDER; BLOOD SMEAR; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; DISEASE SEVERITY; EHLERS DANLOS SYNDROME; FAMILY HISTORY; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HORMONAL THERAPY; HUMAN; MENORRHAGIA; PARTIAL THROMBOPLASTIN TIME; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME; THROMBOCYTE DISORDER; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE;

BLOOD COAGULATION DISORDERS; DISEASE MANAGEMENT; HEMORRHAGE; HUMANS;

EID: 84872107107     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1326783     Document Type: Article

References (72)

1. Silwer J. von Willebrand's disease in Sweden. Acta Paediatr Scand Suppl: 1973; 238 1 159
2. Lak M., Peyvandi F., Mannucci P. M. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol: 2000; 111 4 1236 1239
3. Rodeghiero F., Castaman G., Tosetto A., et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost: 2005; 3 12 2619 2626
4. Srámek A., Eikenboom J. C., Briët E., Vandenbroucke J. P., Rosendaal F. R. Usefulness of patient interview in bleeding disorders. Arch Intern Med: 1995; 155 13 1409 1415
5. Federici A. B. Clinical diagnosis of von Willebrand disease. Haemophilia: 2004; 10 Suppl 4 169 176
6. Favaloro E. J. Rethinking the diagnosis of von Willebrand disease. Thromb Res: 2011; 127 Suppl 2 S17 S21
7. Hayward C. PM. Diagnostic evaluation of platelet function disorders. Blood Rev: 2011; 25 4 169 173
8. Quiroga T., Goycoolea M., Panes O., et al. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. Haematologica: 2007; 92 3 357 365
9. Warner P. E., Critchley H. OD, Lumsden M. A., Campbell-Brown M., Douglas A., Murray G. D. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol: 2004; 190 5 1216 1223
10. Philipp C. S., Faiz A., Dowling N. F., et al. Development of a screening tool for identifying women with menorrhagia for hemostatic evaluation. Am J Obstet Gynecol: 2008; 198 2 163, e1-e8
11. Ang-Lee M. K., Moss J., Yuan C. S. Herbal medicines and perioperative care. JAMA: 2001; 286 2 208 216
12. Nosek-Cenkowska B., Cheang M. S., Pizzi N. J., Israels E. D., Gerrard J. M. Bleeding/bruising symptomatology in children with and without bleeding disorders. Thromb Haemost: 1991; 65 3 237 241
13. Drews C. D., Dilley A. B., Lally C., Beckman M. G., Evatt B. Screening questions to identify women with von Willebrand disease. J Am Med Womens Assoc: 2002; 57 4 217 218
14. Tosetto A., Rodeghiero F., Castaman G., et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost: 2006; 4 4 766 773
15. Federici A. B., Mannucci P. M., Castaman G., et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood: 2009; 113 3 526 534
16. Biss T. T., Blanchette V. S., Clark D. S., et al. Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire. J Thromb Haemost: 2010; 8 5 950 956
17. Biss T. T., Blanchette V. S., Clark D. S., Wakefield C. D., James P. D., Rand M. L. Use of a quantitative pediatric bleeding questionnaire to assess mucocutaneous bleeding symptoms in children with a platelet function disorder. J Thromb Haemost: 2010; 8 6 1416 1419
18. Bowman M., Mundell G., Grabell J., et al. Generation and validation of the condensed MCMDM-1VWD bleeding questionnaire for von Willebrand disease. J Thromb Haemost: 2008; 6 12 2062 2066
19. Bowman M., Riddel J., Rand M. L., Tosetto A., Silva M., James P. D. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J Thromb Haemost: 2009; 7 8 1418 1421
20. Marcus P. D., Nire K. G., Grooms L., Klima J., O'Brien S. H. The power of a standardized bleeding score in diagnosing paediatric type 1 von Willebrand's disease and platelet function defects. Haemophilia: 2011; 17 2 223 227
21. Tosetto A., Castaman G., Plug I., Rodeghiero F., Eikenboom J. Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation. J Thromb Haemost: 2011; 9 6 1143 1148
22. Rodeghiero F., Tosetto A., Abshire T., et al. ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost: 2010; 8 9 2063 2065
23. Mauer A. C., Barbour E. M., Khazanov N. A., Levenkova N., Mollah S. A., Coller B. S. Creating an ontology-based human phenotyping system: The Rockefeller University bleeding history experience. Clin Transl Sci: 2009; 2 5 382 385
24. Mauer A. C., Khazanov N. A., Levenkova N., et al. Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults. J Thromb Haemost: 2011; 9 1 100 108
25. Higham J. M., O'Brien P. M., Shaw R. W. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol: 1990; 97 8 734 739
26. Philipp C. S., Faiz A., Heit J. A., et al. Evaluation of a screening tool for bleeding disorders in a US multisite cohort of women with menorrhagia. Am J Obstet Gynecol: 2011; 204 3 209, e1-e7
27. McKay H., Derome F., Haq M. A., et al. Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood: 2004; 104 1 159 165
28. Beighton P., Solomon L., Soskolne C. L. Articular mobility in an African population. Ann Rheum Dis: 1973; 32 5 413 418
29. Mishra P., Naithani R., Dolai T., et al. Intracranial haemorrhage in patients with congenital haemostatic defects. Haemophilia: 2008; 14 5 952 955
30. Malfait F., De Paepe A. Bleeding in the heritable connective tissue disorders: mechanisms, diagnosis and treatment. Blood Rev: 2009; 23 5 191 197
31. Mehta R., Shapiro A. D. Plasminogen activator inhibitor type 1 deficiency. Haemophilia: 2008; 14 6 1255 1260
32. Carpenter S. L., Mathew P. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance. Haemophilia: 2008; 14 6 1250 1254
33. Podda G. M., Bucciarelli P., Lussana F., Lecchi A., Cattaneo M. Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time. J Thromb Haemost: 2007; 5 12 2393 2398
34. Quiroga T., Goycoolea M., Muñoz B., et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients. J Thromb Haemost: 2004; 2 6 892 898
35. Castaman G., Tosetto A., Goodeve A., et al. The impact of bleeding history, von Willebrand factor and PFA-100(®) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD. Br J Haematol: 2010; 151 3 245 251
36. Hayward C. PM, Harrison P., Cattaneo M., Ortel T. L., Rao A. K.; Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost: 2006; 4 2 312 319
37. Hayward C. PM, Pai M., Liu Y., et al. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. J Thromb Haemost: 2009; 7 4 676 684
38. Hayward C. PM, Moffat K. A., Raby A., et al. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. Am J Clin Pathol: 2010; 134 6 955 963
39. Nieuwenhuis H. K., Akkerman J. W., Sixma J. J. Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients. Blood: 1987; 70 3 620 623
40. Asakai R., Chung D. W., Davie E. W., Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med: 1991; 325 3 153 158
41. Hsieh L., Nugent D. Factor XIII deficiency. Haemophilia: 2008; 14 6 1190 1200
42. Rodeghiero F., Castaman G., Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood: 1987; 69 2 454 459
43. Werner E. J., Broxson E. H., Tucker E. L., Giroux D. S., Shults J., Abshire T. C. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr: 1993; 123 6 893 898
44. Bowman M., Hopman W. M., Rapson D., Lillicrap D., James P. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost: 2010; 8 1 213 216
45. Sadler J. E., Budde U., Eikenboom J. CJ., et al. Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost: 2006; 4 10 2103 2114
46. Stine K. C., Becton D. L. DDAVP therapy controls bleeding in Ehlers-Danlos syndrome. J Pediatr Hematol Oncol: 1997; 19 2 156 158
47. De Paepe A., Malfait F. Bleeding and bruising in patients with Ehlers-Danlos syndrome and other collagen vascular disorders. Br J Haematol: 2004; 127 5 491 500
48. Nurden P., Nurden A. T. Congenital disorders associated with platelet dysfunctions. Thromb Haemost: 2008; 99 2 253 263
49. Mannucci P. M., Tuddenham E. GD. The hemophilias-from royal genes to gene therapy. N Engl J Med: 2001; 344 23 1773 1779
50. Pavlova A., Brondke H., Müsebeck J., Pollmann H., Srivastava A., Oldenburg J. Molecular mechanisms underlying hemophilia A phenotype in seven females. J Thromb Haemost: 2009; 7 6 976 982
51. Mannucci P. M., Duga S., Peyvandi F. Recessively inherited coagulation disorders. Blood: 2004; 104 5 1243 1252
52. Acharya S. S., Coughlin A., Dimichele D. M.; North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost: 2004; 2 2 248 256
53. Franchini M., Lippi G. Acquired factor VIII inhibitors. Blood: 2008; 112 2 250 255
54. Mohri H., Motomura S., Kanamori H., et al. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood: 1998; 91 10 3623 3629
55. Vincentelli A., Susen S., Le Tourneau T., et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med: 2003; 349 4 343 349
56. Uriel N., Pak S-W, Jorde U. P., et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol: 2010; 56 15 1207 1213
57. Meyer A. L., Malehsa D., Bara C., et al. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ Heart Fail: 2010; 3 6 675 681
58. Federici A. B., Rand J. H., Bucciarelli P., et al. Subcommittee on von Willebrand Factor. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost: 2000; 84 2 345 349
59. Tiede A., Rand J. H., Budde U., Ganser A., Federici A. B. How I treat the acquired von Willebrand syndrome. Blood: 2011; 117 25 6777 6785
60. Nichols W. L., Rick M. E., Ortel T. L., et al. Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines. Am J Hematol: 2009; 84 6 366 370
61. James A. H., Kouides P. A., Abdul-Kadir R., et al. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol: 2009; 201 1 12, e1-e8
62. Santagostino E., Mannucci P. M., Bianchi Bonomi A. Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia: 2000; 6 1 1 10
63. Nichols W. L., Hultin M. B., James A. H., et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia: 2008; 14 2 171 232
64. Ansell J., Hirsh J., Hylek E., et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest: 2008; 133 381S 453S
65. Galbusera M., Remuzzi G., Boccardo P. Treatment of bleeding in dialysis patients. Semin Dial: 2009; 22 3 279 286
66. Federici A. B. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007). Haemophilia: 2008; 14 Suppl 1 5 14
67. Franchini M., Zaffanello M., Lippi G. The use of desmopressin in mild hemophilia A. Blood Coagul Fibrinolysis: 2010; 21 7 615 619
68. Bolton-Maggs P. HB, Chalmers E. A., Collins P. W., et al. UKHCDO A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol: 2006; 135 5 603 633
69. Franchini M., Manzato F., Salvagno G. L., Montagnana M., Lippi G. The use of desmopressin in congenital factor XI deficiency: a systematic review. Ann Hematol: 2009; 88 10 931 935
70. Edlund M., Blombäck M., Fried G. Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time. Blood Coagul Fibrinolysis: 2002; 13 3 225 231
71. Lethaby A., Farquhar C., Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane database of systematic reviews (Online). 2000;;CD000249.
72. Ageno W., Gallus A. S., Wittkowsky A., et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest: 2012; 141 e44S 88S